Antiestrogen pathway (aromatase inhibitor).
Z. Desta,A. Nguyen,D. Flockhart,T. Skaar,R. Fletcher,R. Weinshilboum,D. Berlin,T. Klein,R. Altman
DOI: https://doi.org/10.1097/FPC.0b013e32832e0ec1
2009-07-01
Abstract:Description Estrogen plays an important role in initiating and promoting breast cancer Antiestrogen the rate-limiting biosynthesis of estrogen from androgens by aromatase Aromatase, an enzyme of the cytochrome P450 subfamily and the product of the CYP19A1 gene, is highly expressed in the placenta and in the granulose cells of ovarian follicles in premenopausal Its expression depends on cyclical gonadotropin In addition, aromatase is also present at lower levels in several nonglandular tissues that include subcutaneous fat, liver, muscle, brain, normal breast and breast cancer tissue Estrogen production after menopause is solely from nonglandular sources, particularly subcutaneous In menopause, androstenedione produced in the adrenals and, to a small extent, testosterone produced in the ovaries are released to the circulation and then sequestered to nonglandular tissues (e.g. liver and breast cells), where they are converted to estrone and estradiol, respectively, by aromatase located in these tissues In the liver and in breast tissue, estrone and estradiol undergo oxidation by cytochrome P450s to a number of hydroxylated metabolites Estrone and estradiol in these conjugation by